BRIEF — Motif Bio submits Iclaprim NDA

UK-based antibiotics-focused biopharma Motif Bio has announced the completion of its rolling submission of a New Drug Application (NDA) to the US Food & Drug Administration (FDA) for Iclaprim.

A Gram-positive investigational antibiotic, Iclaprim is being developed for the treatment of acute bacterial skin and skin structure infections.

Iclaprim has received Qualified Infectious Disease Product designation from the FDA, together with Fast Track Designation.

Graham Lumsden, chief executive of Motif Bio, said: “We look forward to working with the FDA with the goal of bringing this antibiotic candidate to patients as expeditiously as possible.”